Recently Issued Guidance Documents
Should you find a Web link (URL) embedded within guidance documents that does not work or other documents posted on the FDA Web site, please try searching for the document using the document title. If you need further assistance, please go to Contact FDA.
- Postapproval Pregnancy Safety Studies; Guidance for Industry
CDER/CBER, May 2026 - Submitting Continuous Glucose Monitoring Data in Clinical Trials; Guidance for Industry
CDER/CBER, May 2026 - Chemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products for a Biologics License Application; Guidance for Industry
CBER, May 2026 - Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers; Guidance for Industry
CDER/CBER/OCLiP/OCE, April 2026 - Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing; Draft Guidance for Industry
CBER, April 2026 - Bioanalytical Method Validation for Biomarkers; Guidance for Industry
CDER/CBER, April 2026 - Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle; Guidance for Industry and Food and Drug Administration Staff
CDRH/CBER, March 2026 - Pyrogen and Endotoxins Testing: Questions and Answers; Guidance for Industry
CDER/CBER/CDRH/CVM/ORA, March 2026 - Questions and Answers on Biosimilar Development and the BPCI Act; Guidance for Industry
CDER/CBER, March 2026 - Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection; Draft Guidance for Industry
CDER/CBER/CVM/OII, March 2026 - Considerations for the use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause; Draft Guidance for Industry
CBER/CDER, February 2026 - Computer Software Assurance for Production and Quality Management System Software; Guidance for Industry and Food and Drug Administration Staff
CDRH/CBER, February 2026 - Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions; Guidance for Industry and Food and Drug Administration Staff
CDRH/CBER, February 2026